OCGN Ocugen, Inc.

Nasdaq Biological Products, (No Diagnostic Substances) DE CIK: 0001372299
AI RATING
STRONG_SELL
85% Confidence

Investment Thesis

Ocugen exhibits severe financial distress with only $1.5M revenue supporting $17.8M operating losses and 4.17x debt-to-equity leverage, creating critical solvency risk. Operating cash burn of $21.8M annually exhausts the $31.9M cash position in approximately 1.5 years, while stockholders' equity of $5.8M cannot absorb further losses. Without substantial revenue acceleration or capital restructuring, the company faces significant shareholder value destruction through dilution or insolvency.

Strengths

  • + Positive 8.8% year-over-year revenue growth indicates some commercial traction from product pipeline
  • + Cash position of $31.9M provides immediate operational runway for near-term obligations
  • + Current ratio of 1.86x demonstrates adequate short-term liquidity to cover current liabilities

Risks

  • ! Operating cash burn rate of $21.8M annually with only 1.5 years of runway at current depletion rate
  • ! Extreme leverage with 4.17x debt-to-equity ratio against deteriorating equity base of $5.8M
  • ! Negative 1163.7% operating margin and 1250.9% net margin indicate fundamental business model dysfunction
  • ! Minimal $1.5M revenue base insufficient to service $51.1M total liabilities or reduce debt burden

Key Metrics to Watch

Financial Metrics

Revenue
1.5M
Net Income
-19.2M
EPS (Diluted)
$-0.06
Free Cash Flow
-21.8M
Total Assets
56.9M
Cash
31.9M

Profitability Ratios

Gross Margin N/A
Operating Margin -1,163.7%
Net Margin -1,250.9%
ROE -330.4%
ROA -33.7%
FCF Margin -1,422.0%

Balance Sheet & Liquidity

Current Ratio
1.86x
Quick Ratio
1.86x
Debt/Equity
4.17x
Debt/Assets
89.8%
Interest Coverage
-13.72x
Long-term Debt
24.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-09T08:30:18.856703 | Data as of: 2026-03-31 | Powered by Claude AI